Business Wire

VOOPOO

2.12.2021 10:37:10 CET | Business Wire | Press release

Share
Honor to Knight! DRAG S/X PnP-X Kit Is Launched

In November, VOOPOO announced the overseas launch of the DRAG S/X PnP-X KIT. The product carries out comprehensive technical upgrading on the basis of DRAG S/X, endows the core concept of "Chivalry" in product design, and pays tribute to the glory and virtue of knights.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005381/en/

Originated from the spirit of martial arts of German in the Middle Ages, the spirit of chivalry was then embodied in soldiers of the European battlefield in the 11th century, and guards of emperors and warriors of Christ. Nowadays, chivalry is culturally continued and nobly expressed as gentleman demeanor. Despite passage of time, the only constant is the faith that knight loyally holds and eight virtues of knights flowing in their blood. After learning about this legendary medieval history and digging out the core of chivalry, VOOPOO design and R&D personnel were deeply touched. The four core propositions of " Honor", " Valor", "Justice" and "Spirituality" were included in DRAG S/X PnP-X KIT product for consumers to discover. Every vaping is a fusion of VOOPOO and the connotation of the knight, and every piece of cloud is a spiritual portrait of the knight who rushes to the battlefield heroically.

DRAG S/X PnP-X KIT selects five new knight colors, each of which implies a rich design language. Shield Gold--Knight Templar for Defending Justice. Knight Red--Masked Knight for Pursuit Fairness. Knight Chestnut--Dragon Knight for Defending Glory .Eagle Black--Black Knight for Brave and Fearless. Knight Gray--Paladin for Spirituality.

PnP-X Pod displays knight’s spirituality. The metal materials and knob-filling on the top are upgraded, and the 510 drip tip can be replaced at any time. It is anti-leakage, more convenient, and more flexible. Radiating knight spirituality, PnP-X Pod will give you an enjoyable experience in vaping.

The knight series products bring an "Infinite Airflow System" that supports the adjustment of any airway. More than that, knight symbolizes of bravery and heroism. DRAG S/X PnP-X KIT embodies the knight’s valor spirit. It is equipped with a powerful GENE.TT chip, and adjustable power ranging from 5-60/80w. The product can be started in 0.001 second. The hardware is powerful enough that every knight can charge into the battle, with no worries.

The mission of the knight is to guard the country and territory, glory, and faith, and the beloved princess in their hearts. DRAG S/X PnP-X KIT fitted with 2500 mAh built-in battery and 18650 external battery respectively. The Type-C 5V/2A fast charging interface gives every knight full blood for them to resurrect in an instant. To guard the DRAG S/X PnP-X KIT is to guard the spirit of the knight, the cultural connotation of which has been inherited and innovated for thousands of years.

DRAG S/X PnP-X KIT has been upgraded based on DARG S&DARG X. The biggest highlight is the comprehensive upgrade of the atomizer. For one thing, the PnP X Pod has upgraded the metal decorative ring with knight-style texture. For another, the knob-filling on the top, which is more convenient. Anti-leakage design is more compact, and the 510 drip tip can be replaced at any time. In short, the upgrade of DRAG S/X PnP-X KIT is comprehensive, and is worthy of buying. At the same time, a vaper who likes the appearance of knights can't miss this flagship product with "chivalry spirit." Let us pay tribute to the honor of knights together!

Positioning of DRAG S/X PnP-X KIT and DARG S/X PRO is different. DARG S/X PRO is a top-fitting product for professional vapers who want to experience higher power and bigger cloud.

Founded in 2017, VOOPOO has rapidly grown within a short period of time and is now selling worldwide. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. VOOPOO has more than 3000 employees worldwide and its business covers more than 70 countries and regions in North America, Europe and Asia.

WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.

For more information, please visit https://www.voopoo.com/ , and follow our IG , Facebook and TikTok pages.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye